Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Almirall S.A
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Almirall S.A.
- Almirall LLC
- Aqua Pharmaceuticals
- Taurus Pharma GmbH
- Polichem S.A.
- Polichem S.r.l.